Spots Global Cancer Trial Database for Serum Pepsinogen After H. Pylori Eradication
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Serum Pepsinogen After H. Pylori Eradication
Official Title: Serum Pepsinogen After Helicobacter Pylori Eradication for the Gastric Cancer Prevention
Study ID: NCT03924375
Conditions
Interventions
Study Description
Brief Summary: Helicobacter pylori has been recognized as a major pathogen in gastric carcinogenesis. Current guidelines recommend the H. pylori "test-and-treat" strategy for the purpose of primary and secondary gastric cancer prevention. Considering the "point of no return" theory, however, H. pylori eradication cannot reduce the risk of gastric cancer in subjects with gastric atrophy and intestinal metaplasia. The intragastric hypoacidic environment is associated with the risk of intestinal-type gastric cancer development. Recently, the secretory ability of the stomach can be measured using the serum pepsinogen (PG) assay.
Detailed Description: This study aimed to evaluate the change of serum PGs after H. pylori eradication success and identify the optimal timing of eradication.
Keywords
Eligibility
Minimum Age: 20 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Digestive Disease Center, Soonchunhyang University Hospital, Seoul, , Korea, Republic of
Contact Details
Name: Jun-Hyung Jun-Hyung, M.D.
Affiliation: Digestive Disease Center, Soonchunhyang University Hospital
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
